Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn's Disease: The CHARM Trial
Frontiers | Administration Timing Is the Best Clinical Outcome Predictor for Adalimumab Administration in Crohn's Disease
Efficacy and effectiveness of biologic therapy in inflammatory bowel disease. EFIFECT study | Gastroenterología y Hepatología (English Edition)
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis - Gastroenterology
M02-404 (CSR)
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn's Disease: The CHARM Trial - ScienceDirect
Adalimumab (CLASSIC & CHARM trial - Crohn) | Digestive Disease Dashboard
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study - The Lancet Gastroenterology & Hepatology
Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial - Baili Chen, Xiang Gao, Jie Zhong, Jianlin Ren, Xuan Zhu, Zhanju
Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE - Panaccione - 2013 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
HUMIRA® (adalimumab) for Crohn's Disease in adults
Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn's Disease: The CHARM Trial
Adalimumab (CLASSIC & CHARM trial - Crohn) | Digestive Disease Dashboard
The Efficacy of Anti-TNFs in Immune-Mediated Disease - European Medical Journal
Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE - Panaccione - 2013 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
IJMS | Free Full-Text | A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease
Abbott's response to the Appraisal Consultation Document of adalimumab and infliximab for the treatment of Crohn's disease
![PDF] Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/65eacb27ce81f30a0f2e7ef0d05e54a6f0bc0091/5-Figure2-1.png "PDF] Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. | Semantic Scholar")
PDF] Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. | Semantic Scholar
IJMS | Free Full-Text | Tumor Necrosis Factor's Pathway in Crohn's Disease: Potential for Intervention
Adalimumab for the treatment of fistulas in patients with Crohn's disease | Gut
25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future | Gut
